$NSTS

NSTS Bancorp, Inc. (NSTS): Completion of Acquisition or Disposition of Assets

NSTS Bancorp, Inc. (NSTS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01. Completion of Acquisition or Disposition of Assets. As of the Effective Time, the Company merged with Merger Sub, with the Company as the surviving corporation (the “ Merger ”), and immediately thereafter merged with and into Brookfield, with Brookfield as the survivin

Original reporting
Published Oct 1, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 12:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$NSTS
Bearish
high confidence
Mentioned
$NSTS
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NSTSBearishHigh
01

Why it matters

The merger eliminates NSTS's public float, delivering a $14.31 per share cash payment and ending all shareholder voting rights.

02

Market read

The filing provides the first public details of the merger and delisting, creating immediate trading relevance for NSTS shareholders.

03

What to watch

Potential tax implications for shareholders and the strategic fit of Brookfield's broader banking platform.

Relevance 7/10Novelty 8/10Timing: effective immediately after filing

Background

NSTS Bancorp completed a two‑step merger, becoming a wholly owned subsidiary of Brookfield Bancshares, and filed a delisting notice with Nasdaq.

Company-level read

Ticker impact

$NSTSBearishHigh confidence
Context

SEC 8‑K reports NSTS Bancorp's merger into Brookfield, resulting in delisting and cash payout of $14.31 per share.

Expected impact

downward pressure as investors sell before delisting and cash distribution.

Evidence & confidence

The merger is a primary disclosure with cash consideration, and the imminent delisting removes the public market for the ticker.

Market effects

Banking sector sees consolidation; peers may face similar M&A pressure.

U.S. regional banks may experience short-term volatility as investors reassess exposure.

Limited to U.S. small‑cap banking niche; minimal global impact.

Counterpoint

Some investors may view the cash payout as a premium and consider buying before delisting to capture the distribution.

Key entities

  • NSTS Bancorp, Inc.

    Target of the merger, formerly listed on Nasdaq.

  • Brookfield Bancshares, Inc.

    Acquirer and successor to NSTS.

Related articles

$JOBYMed

Joby Aviation stock hits 52-week low at $5.93

Joby Aviation (JOBY) hit a 52-week low of $5.93, down 62.7% over the past year. Despite this, InvestingPro analysis suggests the stock is undervalued. The company reported Q2 2026 revenue of $38.6M, up from $15K in the same quarter last year, and acquired Resonant Sciences for $500M. Analysts have mixed ratings and price targets.

$SWKSHighAI 9/10

RBC Capital raises Skyworks Solutions price target on deal approval

RBC Capital raised Skyworks Solutions' (SWKS) price target to $95 from $70, citing regulatory approval for its Qorvo acquisition. The deal, expected to close by October 2026, is seen as favorable due to potential synergies. SWKS stock has risen 30% in the past month and 62% in six months, trading at $85.86. The company recently reported Q3 earnings of $1.08 per share on $935M revenue, beating estimates.

$XRPNHighAI 8/10

Evernode to List on Nasdaq Oct. 8 Through SPAC Merger

Evernode, an XRP-based digital-asset treasury company, will list on Nasdaq on Oct. 8 through a merger with Armada Acquisition Corp. II. The deal provides $300M in cash, including a $225M private investment. Post-merger, Evernode will hold 473M XRP, the largest among listed companies. The combined company will trade under the ticker XRPN.

$SNYHighAI 9/10

Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion

Sanofi (SNY) and Regeneron expanded their DUPIXENT alliance with a deal worth up to €8 billion. The collaboration includes three preclinical programs targeting IL-4/IL-13 pathways. Sanofi reported DUPIXENT's Q2 2026 global net sales at EUR 5.2 billion, annualizing over EUR 20 billion. The deal resolves litigation and outlines governance roles. Regeneron gains development authority, while Sanofi retains commercial rights.